Natera touts data supporting personalized ctDNA testing

By staff writers

July 7, 2020 -- Natera is highlighting clinical data that supports the efficacy of personalized circulating tumor DNA (ctDNA) testing for oligometastatic colorectal cancer.

The data were presented at the virtual European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer, which was held from July 1 to 4, and support the validity of Natera's Signatera ctDNA test for identifying molecular residual disease in patients with this type of cancer. The test is customized for each individual, based on the clonal mutations in his or her tumor, according to the company.

A prospective trial in progress will measure clinical outcomes of molecular residual disease-guided treatment in oligometastatic colorectal cancer patients with stage II to III disease, Natera said.

AI predicts which patients to test for pancreatic cancer
Researchers created a model utilizing artificial intelligence (AI) that identified patients at an increased risk for pancreatic cancer who could benefit...
Natera files patent lawsuit against Progenity
Natera has filed a lawsuit against Progenity for infringing six U.S. patents.
New technique improves Natera's organ transplant test
Natera has launched a new technique that enhances results from Prospera, the company's donor-derived cell-free DNA organ transplant laboratory-developed...
Natera's prenatal testing coverage expands
A national insurer has expanded coverage of Natera's Panorama cell-free DNA and noninvasive prenatal test to all pregnant women, regardless of age. Natera...
Natera releases pricing for Prospera cell-free DNA test
Cell-free DNA testing company Natera has released pricing for its Prospera donor-derived cell-free DNA organ transplant laboratory-developed test.

Copyright © 2020

Last Updated ls 7/7/2020 11:00:07 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.